insitro will receive $40 million upfront and may earn approximately $1.46 billion in milestones under an agreement giving AstraZeneca exclusive global rights to selected programmes. IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca has entered into a strategic drug discovery and licensing collaboration with … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged AI drug discovery, AstraZeneca, AstraZeneca and insitro Launch AI Collaboration to Discover Therapies for Cardiometabolic Diseases, AstraZeneca Enlists Virtual Human AI Platform to Investigate MASH and Cardiomyopathy Targets, AstraZeneca Secures Global Rights to Selected AI-Discovered Programmes in insitro Agreement, BioPharmaceuticals R&D, Cambridge, cardiometabolic disease, cardiomyopathies, clinical development, Daphne Koller, drug targets, insitro, insitro to Receive $40 Million Upfront in AstraZeneca Cardiometabolic Drug Discovery Deal, MASH, metabolic dysfunction-associated steatohepatitis, Sharon Barr, therapeutic discovery, Virtual Human AI platform
The first Russell Group university campus in Karnataka launches with five subject areas and new academic and industry partnerships linking India and the UK. IN BRIEFKEY TAKEAWAYSFAQs The University of Liverpool officially opened its Bengaluru campus on 15 October 2026, … Read the full press release
Posted in Business, Education, International Trade, United Kingdom
Tagged Accounting and Finance, Alembic City, Alison Barrett, AstraZeneca, Axis Bank, Bell Integration, Bengaluru, biomedical sciences, Business Management, Computer Science, D. K. Shivakumar, Dream11, Game Design, Har Gobind Khorana, Harshbir Sangha, IISc Bengaluru, INDIA, Indian Institute of Science, India–UK Free Trade Agreement, India–UK higher education, Karnataka, Liverpool, Liverpool University Marks Bengaluru Opening with Research and Industry Agreements, M. B. Patil, National Centre for Biological Sciences, National Institute of Mental Health and Neurosciences, NCBs, Nearly 300 Students Join University of Liverpool’s New Bengaluru Campus, NIMHANS, Professor Tim Jones, RCOG, Robbie Fowler, Russell Group, Sai Life Sciences, Shilpa Nag, Steve Rotheram, TiE Bangalore, Tim Games, United Kingdom, University of Liverpool, University of Liverpool Bengaluru, University of Liverpool Establishes First Russell Group Campus in Karnataka, University of Liverpool Expands India–UK Education Collaboration with Bengaluru Launch, Whitefield, Wipro Limited, YouWeCan
Associate Director brings more than 20 years of property experience to the role, supporting developers and buyers across Cambridge IN BRIEFKEY TAKEAWAYSFAQs Savills has appointed Associate Director Ashley Gale to head its new homes team in Cambridge. Gale, who joined … Read the full press release
Posted in Management, Real Estate, United Kingdom
Tagged Addenbrooke’s, Ashley Gale, Ashley Gale takes charge of Savills Cambridge new homes operations, AstraZeneca, Cambridge, Cambridge Biomedical Campus, Cambridge new homes, Cambridge South station, GSK, Hopkins Homes, housing developers, property sector appointments, residential development sales, Royal Papworth hospitals, Savills, Savills appoints Ashley Gale to manage residential development sales in Cambridge, Savills promotes property specialist Ashley Gale to lead Cambridge new homes team, Savills strengthens Cambridge residential sales leadership with Ashley Gale appointment, Tom Fraser, United Kingdom, Weston Homes
Week-25 walking distance improved numerically by 17.05 metres versus placebo, while fatigue and selected subgroup outcomes showed nominal benefits IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca announced Phase III HICKORY findings for investigational efzimfotase alfa in 124 treatment-naïve adolescents and adults with hypophosphatasia. … Read the full press release
Posted in European Union, France, Germany, Healthcare, Italy, Pharma & Biotech, Science, Spain, United Kingdom
Tagged Alexion, ALXN1850, American Society for Bone and Mineral Research, ASBMR 2026, asfotase alfa, AstraZeneca, AstraZeneca details HICKORY subgroup outcomes as efzimfotase alfa receives US Priority Review, AstraZeneca HICKORY data show numerical walking improvement without statistically significant primary endpoint, AstraZeneca Rare Disease, Boston, CHESTNUT trial, clinical trials, efzimfotase alfa, Efzimfotase alfa demonstrates nominal fatigue improvement in HICKORY Phase III rare disease study, enzyme replacement therapy, FACIT-Fatigue, Gianluca Pirozzi, HICKORY Phase III trial, HICKORY Phase III trial reports week-49 extension gains in hypophosphatasia patients receiving efzimfotase alfa, HPP, hypophosphatasia, Kathryn Dahir, MULBERRY trial, rare disease, Six-Minute Walk Test, Strensiq, US FDA Priority Review
The 570,000-square-foot Cambridge facility will work alongside AstraZeneca’s genomic medicine site at 100 Binney Street and support nearly 2,000 researchers and scientists. IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca has opened a new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, as … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, Investment, Pharma & Biotech, Science
Tagged 100 Binney Street, 290 Binney Street, agentic AI, AstraZeneca, AstraZeneca expands Massachusetts research footprint with new Kendall Square R&D centre, AstraZeneca opens 570000-square-foot Kendall Square research hub focused on next-generation medicines, AstraZeneca R&D Center Kendall Square, AstraZeneca’s $1 billion Massachusetts investment advances with opening of Cambridge R&D centre, biologics, breast cancer, Cambridge Massachusetts, cell therapy, chronic disease, continuous automation, COPD, Gaithersburg Maryland, genomic medicine, Kendall Square, life sciences, Massachusetts, Maura Healey, metabolic disease, New AstraZeneca Kendall Square facility to bring nearly 2000 researchers and scientists together in Cambridge, Obesity, oncology, Pascal Soriot, rare disease, research and development, robotics, STEM education, United States, workforce development
Phase III HICKORY results for efzimfotase alfa and CALYPSO skeletal data for eneboparatide are among three oral presentations in Boston from 9 to 12 October 2026. IN BRIEFKEY TAKEAWAYSFAQs Alexion, AstraZeneca Rare Disease, will deliver 16 presentations, including three oral … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged Alexion, Alexion brings HICKORY and CALYPSO Phase III findings to ASBMR 2026 in Boston, Alexion highlights efzimfotase alfa and eneboparatide research at the 2026 ASBMR meeting, ALXN1850, American Society for Bone and Mineral Research, ASBMR 2026 Annual Meeting, ASBMR 2026 programme to feature Alexion data on HPP, HypoPT and early research, AstraZeneca, AstraZeneca Rare Disease, AstraZeneca Rare Disease outlines 16 ASBMR 2026 presentations across HPP and chronic hypoparathyroidism, Boston, calypso, chronic hypoparathyroidism, efzimfotase alfa, Eneboparatide, Gianluca Pirozzi, HICKORY, HPP, hypophosphatasia, HypoPT, Massachusetts, Phase III clinical trials, rare disease research, United Kingdom, United States
Investment will support development of the PD-1/VEGF bispecific with sonesitatug vedotin and other AstraZeneca cancer medicines, including additional ADCs IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca has completed its $2 billion equity investment in Summit Therapeutics, with the funding intended to accelerate development … Read the full press release
Posted in Healthcare, Investment, Pharma & Biotech, Science, United Kingdom
Tagged $2 billion investment, ADCs, antibody-drug conjugates, AstraZeneca, AstraZeneca and Summit advance ivonescimab combination programme following completion of $2 billion investment, AstraZeneca closes $2 billion Summit Therapeutics equity investment for ivonescimab ADC combinations, AstraZeneca completes Summit investment as companies progress ivonescimab clinical collaborations, AstraZeneca finalises $2 billion Summit Therapeutics investment to accelerate ivonescimab combination development, AstraZeneca PLC, breast cancer, Cambridge, cancer medicines, clinical collaboration, Completed AstraZeneca investment supports expanded ivonescimab combinations with cancer medicines, Daiichi Sankyo, datopotamab deruxtecan, Datroway, equity investment, ivonescimab, lung cancer, oncology, PD-1, Sone-Ve, sonesitatug vedotin, Summit Therapeutics, United Kingdom, VEGF
The collaboration is set to begin with a Phase III trial in first-line triple-negative breast cancer, with the partners sharing trial costs while retaining rights to their respective medicines. IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca and Daiichi Sankyo have entered into a … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, AstraZeneca and Daiichi Sankyo expand ADC combination strategy with Summit’s ivonescimab, AstraZeneca, Daiichi Sankyo and Summit plan Datroway–ivonescimab clinical programme across multiple cancers, breast cancer, Daiichi Sankyo, datopotamab deruxtecan, Datroway, Datroway and ivonescimab combination to enter Phase III study under new AstraZeneca, Daiichi Sankyo and Summit collaboration, Dr. Maky Zanganeh, DXd ADC Technology, EGFR, ivonescimab, John Tsai, lung cancer, New clinical collaboration will test Datroway with ivonescimab in lung, breast and other tumour types, non-small cell lung cancer, NSCLC, PD-1, Phase III, Sone-Ve, sonesitatug vedotin, Summit Therapeutics, Susan Galbraith, TNBC, triple-negative breast cancer, TROP2, TROPION-Breast01, TROPION-Breast02, TROPION-Lung01, TROPION-Lung05, VEGF
(IN BRIEF) AstraZeneca’s supplemental Biologics License Application for Imfinzi in combination with enfortumab vedotin has been accepted and granted Priority Review by the US FDA for patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy. … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Security & Safety, United Kingdom
Tagged antibody-drug conjugate, AstraZeneca, AstraZeneca Secures Priority Review for Perioperative Imfinzi Regimen in Cisplatin-Ineligible Bladder Cancer, AstraZeneca Targets Q4 2026 FDA Decision for Imfinzi Combination in Muscle-Invasive Bladder Cancer, AstraZeneca’s VOLGA Trial Supports US Priority Review of Imfinzi and Enfortumab Vedotin in MIBC, Bacillus Calmette-Guérin, BCG, bladder cancer, cisplatin, cisplatin-based chemotherapy, cisplatin-ineligible patients, curative-intent treatment, durvalumab, EFS, enfortumab vedotin, European Union, EV, event-free survival, FDA, fourth quarter 2026, Imfinzi, immunotherapy, Japan, metastatic urothelial cancer, MIBC, muscle-invasive bladder cancer, neoadjuvant treatment, NIAGARA Phase III trial, NILE Phase III trial, non-muscle-invasive bladder cancer, Oncology Haematology R&D, OS, overall survival, PD-L1, PDUFA, perioperative treatment, POTOMAC Phase III trial, Priority Review, radical cystectomy, regulatory review, sBLA, September 25 2026, supplemental Biologics License Application, Susan Galbraith, urothelial cancer, US Food and Drug Administration, VOLGA Phase III trial
(IN BRIEF) Alexion, AstraZeneca Rare Disease, will present 15 studies at the 2026 AANEM Annual Meeting and MGFA Scientific Session in Orlando from 29 September to 2 October, with a major focus on investigational gefurulimab and broader advances in generalised … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AANEM Annual Meeting, AChR antibody-positive gMG, Ad Scientiam, Alexion, Alexion Reports Sustained 52-Week Clinical Improvements with Investigational Gefurulimab in PREVAIL Extension, Alexion to Present Long-Term PREVAIL Results for Investigational Gefurulimab Across 15 gMG Studies, Alexion to Showcase 15 Presentations on Generalised Myasthenia Gravis at AANEM and MGFA Scientific Sessions, American Association of Neuromuscular & Electrodiagnostic Medicine, anti-acetylcholine receptor antibody, AstraZeneca, AstraZeneca Rare Disease, C5 inhibitor, Christophe Hotermans, clinical deterioration, complement C5 inhibition, corticosteroid tapering, Digital Biomarkers, DOMYA study, dual-binding nanobody, efgartigimod, gefurulimab, gefurulimab 52-week data, generalised myasthenia gravis, gMG, healthcare resource utilisation, hospitalisation, ME&MG, meningococcal infections, MG SPOTLIGHT Registry, MG-ADL, MGC, MGFA Scientific Session, minimal symptom expression, myasthenia gravis, Myasthenia Gravis Composite, Myasthenia Gravis Foundation of America, neuromuscular disease, neuromuscular junction, NMJ, Octagon study, once-weekly treatment, Orlando, Phase III, Phase IV, PREVAIL open-label extension, PREVAIL Phase III trial, QMG, quality of life, Quantitative Myasthenia Gravis, rare disease, ravulizumab, rescue therapy, self-administered treatment, subcutaneous treatment, translational biomarker
(IN BRIEF) AstraZeneca’s Trixeo Aerosphere has been approved by the European Commission as a maintenance treatment for asthma in patients aged 12 years and older whose disease is not adequately controlled by medium-dose ICS/LABA therapy. AstraZeneca describes Trixeo as the … Read the full press release
Posted in Business, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, United Kingdom
Tagged 363 million people worldwide, 43 million people, 4300 patients, 6.8 million patients, Aerosphere, Alberto Papi, asthma, AstraZeneca, AstraZeneca Broadens Respiratory Portfolio With European Approval of Trixeo Aerosphere for Asthma, AstraZeneca Expands Trixeo Aerosphere into Asthma Treatment Across the European Union, AstraZeneca’s Trixeo Approved in Europe for Asthma Uncontrolled on Dual Inhaled Therapy, BGF, biopharmaceuticals, Breztri, Breztri Aerosphere, budesonide, Cambridge, CHMP, Chronic obstructive pulmonary disease, Committee for Medicinal Products for Human Use, COPD, EMA, European Commission, European Medicines Agency, European Union, FEV1, formoterol fumarate dihydrate, glycopyrronium, ICS, inhaled corticosteroid, KALOS trial, LABA, LAMA, LOGOS trial, long-acting beta2-agonist, long-acting muscarinic antagonist, lung function, maintenance treatment, Phase III, PT009, Respiratory & Immunology, respiratory medicine, Ruud Dobber, S. Anna University Hospital, severe asthma exacerbations, single inhaler, Symbicort, triple-combination therapy, Trixeo, Trixeo Aerosphere, uncontrolled asthma, United Kingdom, University of Ferrara
(IN BRIEF) AstraZeneca has launched a new five-year phase of its Young Health Programme, taking the company’s cumulative investment in youth health equity to more than $100 million since the initiative began in 2010. Delivered with UNICEF and more than … Read the full press release
Posted in Business, Healthcare, Investment, Non Profit, Pharma & Biotech, Science, Society, United Kingdom
Tagged $4.30 social return, 1 million people trained, 10 million young people, 17 public policies, 23 million young people reached, 29 laws and policies, 800000 youth advocates, adolescence, adolescent health, air pollution, alcohol use, Alexion, AstraZeneca, AstraZeneca Builds on 15 Years of Young Health Programme With Expanded UNICEF and NGO Partnership, AstraZeneca Expands Young Health Programme With $100 Million-Plus Investment and New 2030 Targets, AstraZeneca Strengthens Youth-Led Health Action Through New Five-Year Young Health Programme Phase, Cambridge, Cancer Prevention, Catherine Russell, climate change and health, climate health impacts, climate responsiveness, diabetes prevention, global health, Health Education, Health Equity, health systems, heart disease prevention, Johns Hopkins Bloomberg School of Public Health, Kristin Mmari, lung disease prevention, Marc Dunoyer, more than 60 countries, NCDs, non-communicable diseases, One Young World, physical inactivity, Plan International, poor diet, preventive health, public health, public policy, RTI International, social return on investment, tobacco use, underserved communities, UNICEF, YHP, Young Health Programme, youth advocacy, youth health, youth health equity, youth-led action, £100 million commitment
(IN BRIEF) Alexion, AstraZeneca Rare Disease, has received FDA Priority Review for its Biologics License Application for investigational efzimfotase alfa (ALXN1850) in patients with hypophosphatasia aged two years and older, with a regulatory decision anticipated in the first half of … Read the full press release
Posted in Business, Healthcare, Industrial, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 6MWT, adolescent HPP, adult HPP, Alexion, Alexion’s Efzimfotase Alfa Granted FDA Priority Review for Hypophosphatasia Patients Aged Two Years and Older, alkaline phosphatase, ALP, ALPL gene, ALXN1850, American Society for Bone and Mineral Research, ASBMR, asfotase alfa, AstraZeneca, AstraZeneca Rare Disease, AstraZeneca Rare Disease Advances Efzimfotase Alfa Toward US Regulatory Decision Following FDA Priority Review, Biologics License Application, biweekly dosing, BLA, bone mineralisation, BOT-2, BPI-SF, Brief Pain Inventory Short Form, Bruininks-Oseretsky Test of Motor Proficiency, calcium regulation, CHESTNUT, efzimfotase alfa, enzyme replacement therapy, ERT, FACIT-Fatigue, fatigue, FDA, FDA Grants Priority Review to Alexion’s Efzimfotase Alfa Following Phase III Programme in Hypophosphatasia, first half 2027, functional impairments, HICKORY, HPP, HPP clinical programme, hypophosphatasia, ICCBH, inherited metabolic disease, injection-site reactions, International Conference on Children’s Bone Health, Japan regulatory review, LEFS, Lower Extremity Functional Scale, Marc Dunoyer, MULBERRY, muscle weakness, neurological symptoms, orphan drug designation, paediatric HPP, pain, PDMS-3, PDUFA, Peabody Developmental Motor Scales, Phase 3 clinical trials, Phase III, phosphate regulation, PLP, Priority Review, pyridoxal 5'-phosphate, Radiographic Global Impression of Change, rare disease, rare disease treatment, RGI-C, Rickets Severity Score, RSS, self-administration, September 18 2026, Six-Minute Walk Test, skeletal abnormalities, Strensiq, Subcutaneous Injection, TEAEs, treatment-emergent adverse events, US Food and Drug Administration
(IN BRIEF) AstraZeneca and Amgen reported positive high-level results from the Phase III CROSSING trial of Tezspire (tezehpelumab) in eosinophilic esophagitis (EoE), showing statistically significant and clinically meaningful improvements versus placebo across both co-primary endpoints and all key secondary endpoints … Read the full press release
Posted in Business, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, United Kingdom
Tagged adults and adolescents, Amgen, Amsterdam University Medical Center, Arjan Bredenoord, AstraZeneca, BioPharmaceuticals R&D, CHINA, chronic inflammatory disorder, Chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, COPD, CROSSING trial, CRSwNP, dietary restriction, disease control, DSQ, dysphagia, Dysphagia Symptom Questionnaire, EMBARK trial, EoE, eosinophilic esophagitis, epithelial cytokine, epithelial-driven inflammatory disease, esophageal inflammation, esophageal narrowing, esophageal tissue, European Union, every four weeks, first-in-class therapy, food impaction, histologic remission, immunology medicine, inflammatory cascades, Japan, JOURNEY trial, maintenance therapy, medical meeting, monoclonal antibody, peak eosinophils, Phase III CROSSING, Phase III Trial, placebo, proton pump inhibitors, regulatory authorities, remission, respiratory medicine, Severe Asthma, Sharon Barr, subcutaneous administration, swallowed topical corticosteroids, symptom improvement, symptomatic uncontrolled EoE, tezepelumab, Tezspire, Tezspire Delivers Positive Phase III Results in Eosinophilic Esophagitis, Tezspire Shows Positive Phase III Results in Eosinophilic Esophagitis Trial, Tezspire Shows Sustained Disease and Symptom Improvements in EoE Trial, thymic stromal lymphopoietin, TSLP, United States, week 24, week 52
(IN BRIEF) AstraZeneca has entered into an exclusive global licence agreement with Dizal Pharmaceutical for Zegfrovy, also known as sunvozertinib, an oral irreversible EGFR inhibitor for lung cancer. The deal gives AstraZeneca worldwide rights to develop and commercialise the medicine. … Read the full press release
Posted in Business, Financial, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged American Society of Clinical Oncology, ASCO 2026, AstraZeneca, AstraZeneca Adds Zegfrovy to Oncology Pipeline Through Global Licence Deal With Dizal, AstraZeneca Targets EGFR Exon 20 Lung Cancer With Worldwide Rights to Zegfrovy, breakthrough therapy designation, cancer treatment, CDE, Center for Drug Evaluation, Dave Fredrickson, Dizal Grants AstraZeneca Global Development and Commercialisation Rights for Zegfrovy, Dizal Pharmaceutical, Dr Xiaolin Zhang, EGFR exon 20 insertion mutations, EGFR inhibitor, EGFR-mutated NSCLC, first-line NSCLC, global licence agreement, irreversible EGFR inhibitor, lung cancer, NCCN Guidelines, New England Journal of Medicine, non-small cell lung cancer, NSCLC, oncology, oncology haematology, oral EGFR inhibitor, pharmaceutical licensing, Phase III Trial, platinum-based chemotherapy, sunvozertinib, Supplemental New Drug Application, targeted therapy, US FDA, WU-KONG28, Zegfrovy
(IN BRIEF) AstraZeneca and Daiichi Sankyo have secured European Union approval for Enhertu as a tumour-agnostic monotherapy for adults with previously treated HER2-positive IHC 3+ unresectable or metastatic solid tumours who have no satisfactory treatment alternatives. The decision is the … Read the full press release
Posted in Business, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, Benedikt Westphalen, biomarker testing, breast cancer, cancer treatment, CHMP, colorectal cancer, Daiichi Sankyo, Dave Fredrickson, DESTINY-Breast01, DESTINY-CRC02, DESTINY-Lung01, DESTINY-PanTumor02, EMA, Enhertu, Enhertu Approval Brings HER2-Directed Antibody Drug Conjugate Therapy to Broader Solid Tumour Population, European Commission, European Medicines Agency, gastric cancer, HER2 testing, HER2-positive solid tumours, Ken Keller, metastatic cancer, New EU Enhertu Indication Expands Targeted Treatment Options Beyond Individual Tumour Types, non-small cell lung cancer, objective response rate, oncology, Phase II Evidence Supports EU Tumour-Agnostic Approval of Enhertu for HER2-Positive Cancers, precision oncology, targeted therapy, trastuzumab deruxtecan, tumour-agnostic therapy, unresectable cancer
(IN BRIEF) The Institute of Cancer Research, London, has welcomed the US FDA approval of capivasertib for patients with PTEN-deficient advanced prostate cancer, marking the first regulatory approval of the targeted drug in prostate cancer. Capivasertib blocks AKT, a cancer-driving … Read the full press release
Posted in Business, Education, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged 3D protein structure, abiraterone, advanced cancer, advanced prostate cancer, AKT inhibitor, AKT pathway, AKT1 mutations, Astex Pharmaceuticals, AstraZeneca, breast cancer, cancer cell growth, cancer cell survival, cancer progression, Cancer Research Technology Limited, Cancer Research UK, CAPItello-281 trial, CAPItello-291 trial, capivasertib, Capivasertib Gains First Prostate Cancer Approval Following Decades of ICR-Led AKT Research, Centre for Cancer Drug Discovery, drug discovery, European Union, FDA, FDA Approval of Capivasertib Marks New Targeted Treatment Option for Advanced Prostate Cancer, fragment-based drug design, fulvestrant, HER2-negative breast cancer, HR-Positive Breast Cancer, ICR, ICR Welcomes FDA Approval of Capivasertib for PTEN-Deficient Advanced Prostate Cancer, ICR Welcomes Milestone FDA Decision for Targeted Therapy in PTEN-Deficient Prostate Cancer, Nature Communications, Nice, oncology research, overall survival, Phase III Trial, PI3 kinase pathway, PIK3CA mutations, precision oncology, Professor Kristian Helin, Professor Paul Workman, prostate cancer patients, prostate cancer treatment, PTEN-deficient prostate cancer, PTEN-deficient tumours, regulatory approval, small molecule inhibitors, targeted therapy, The Institute of Cancer Research, United Kingdom
(IN BRIEF) Alexion, AstraZeneca Rare Disease, has secured FDA acceptance and Priority Review for its supplemental Biologics License Application for Ultomiris as a potential treatment for adults with immunoglobulin A nephropathy, a rare inflammatory kidney disease that can progress to … Read the full press release
Posted in European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Alexion, Alexion’s Ultomiris Receives Priority Review in the US for Adults Living with Immunoglobulin A Nephropathy, ALXN1210-IgAN-320, AstraZeneca, AstraZeneca Rare Disease, AstraZeneca Rare Disease Advances Ultomiris Regulatory Review in the US for Rare Kidney Disease IgAN, atypical haemolytic uraemic syndrome, C5 complement inhibitor, Chronic kidney disease, complement science, EGFR, end-stage kidney disease, estimated glomerular filtration rate, European Renal Association Congress, FDA priority review, generalised myasthenia gravis, glomeruli, I CAN Phase III trial, IgAN, immunoglobulin A nephropathy, inflammation, Marc Dunoyer, nephrology, neuromyelitis optica spectrum disorder, paroxysmal nocturnal haemoglobinuria, PDUFA, proteinuria, rare disease medicine, rare kidney disease, ravulizumab, sBLA, supplemental Biologics License Application, terminal complement pathway, Ultomiris, Ultomiris Moves Toward Potential US Approval in IgAN After Interim Phase III Data Show Significant Proteinuria Reduction, UPCR, urine protein creatinine ratio, US Food and Drug Administration
(IN BRIEF) AstraZeneca announced positive interim Phase III VOLGA trial results showing that perioperative Imfinzi combined with neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, AstraZeneca Expands Immunotherapy Momentum in Bladder Cancer with Positive Phase III VOLGA Trial Readout, AstraZeneca oncology, bladder cancer, Cancer Immunotherapy, cancer recurrence, cancer treatment, cisplatin-ineligible patients, clinical trial results, CTLA-4, durvalumab, enfortumab vedotin, EV, event-free survival, Imfinzi, Imjudo, immunotherapy, MIBC, muscle-invasive bladder cancer, NIAGARA trial, NILE trial, oncology, oncology research, overall survival, PD-L1 inhibitor, Phase III Trial, POTOMAC trial, radical cystectomy, survival outcomes, Susan Galbraith, Thomas Powles, tremelimumab, urothelial carcinoma, VOLGA Phase III Results Position AstraZeneca’s Imfinzi Regimen as Promising New Option for Cisplatin-Ineligible Bladder Cancer Patients, VOLGA trial
(IN BRIEF) AstraZeneca has secured FDA approval for a new subcutaneous autoinjector version of Saphnelo, enabling once-weekly self-administration for adults with systemic lupus erythematosus. The approval is based on Phase III trial results showing significant reductions in disease activity compared … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged anifrolumab, AstraZeneca, AstraZeneca introduces new subcutaneous Saphnelo delivery method to improve convenience and outcomes in lupus care, autoimmune disease, autoinjector, biologic therapy, Bristol-Myers Squibb, clinical trials, FDA, Healthcare Innovation, Louise Vetter, Lupus Foundation of America, Medarex, Ruud Dobber, Saphnelo, SLE, Susan Manzi, systemic lupus erythematosus, TULIP-SC, U.S. Food and Drug Administration
(IN BRIEF) AstraZeneca and Alexion have reported positive interim Phase III results for Ultomiris in treating immunoglobulin A nephropathy, showing a significant reduction in proteinuria compared to placebo. The therapy demonstrated rapid effects as early as week 10 and met … Read the full press release
Posted in Business, Healthcare, Investment, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, AstraZeneca, AstraZeneca Advances Kidney Disease Pipeline with Promising Results for Ultomiris in Global Study, biologics, Chronic kidney disease, clinical research, complement system, end-stage kidney disease, I CAN study, IgAN, immunoglobulin A nephropathy, Jonathan Barratt, kidney disease, Marc Dunoyer, nephrology, New Phase III Data Support Potential of Ultomiris as Disease-Modifying Therapy in IgA Nephropathy, Phase III Trial, proteinuria, rare diseases, ravulizumab, renal medicine, treatment development, Ultomiris
(IN BRIEF) AstraZeneca has received approval from the European Commission for the use of Imfinzi (durvalumab) in combination with FLOT chemotherapy as a perioperative treatment for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. The approval … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, AstraZeneca Expands Oncology Portfolio as EU Approves Imfinzi-Based Regimen for Early Gastric and GEJ Cancer, cancer immunotherapy approval, Committee for Medicinal Products for Human Use, Dave Fredrickson, durvalumab, EU cancer treatment authorization, European Commission, event-free survival, FLOT chemotherapy, Gastric Cancer Treatment, gastroesophageal junction cancer, Imfinzi, immunotherapy oncology, Josep Tabernero, MATTERHORN trial, MATTERHORN Trial Results Lead to EU Approval of Imfinzi Immunotherapy for Early-Stage Gastric Cancer Treatment, oncology clinical trials, overall survival, Vall d'Hebron University Hospital, Vall d’Hebron Institute of Oncology
(IN BRIEF) AstraZeneca has announced a $15 billion investment in China through 2030 to expand research, development and manufacturing capabilities, supporting its long-term growth strategy and global pipeline in advanced treatment modalities such as cell therapy and radioconjugates. The investment … Read the full press release
Posted in Business, Healthcare, Investment, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged advanced medicines, AstraZeneca, AstraZeneca Accelerates 2030 Strategy with $15 Billion China Investment in Breakthrough Therapies and Manufacturing, biopharmaceutical expansion, cell therapy, China investment, China UK healthcare collaboration, global R&D centres, healthcare ecosystem, Healthy China 2030, Keir Starmer, life sciences strategy, oncology innovation, Pascal Soriot, pharmaceutical manufacturing, radioconjugates, research and development
(IN BRIEF) AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong results from the Phase III KOMET trial, which showed a 20% … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 PN, Alexion, Annette Bakker, ASCO 2025, AstraZeneca, AstraZeneca Expands Koselugo’s Clinical Reach with New US Approval for Adults Living with Inoperable NF1 Plexiform Neurofibromas, Children’s Tumor Foundation, FDA approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, paediatric NF1 PN, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease treatment, regulatory approval, selumetinib, The Lancet, tumour response rate
(IN BRIEF) SAP SE and Snowflake have joined forces to integrate SAP Business Data Cloud with Snowflake’s AI Data Cloud, enabling enterprises to access and utilize semantically rich data seamlessly across both platforms. The collaboration introduces the SAP Snowflake solution … Read the full press release
Posted in Artificial Intelligence (AI), Business, Germany, Industrial, Infrastructure & Utilities, Management, News, Technology
Tagged AI applications, AI Data Cloud, analytics, AstraZeneca, business data fabric, business transformation, Christian Kleinerman, cloud computing, Data Intelligence, data sharing, enterprise AI, Irfan Khan, Machine Learning, SAP, SAP BDC, SAP BDC Connect, SAP Business Data Cloud, SAP Expands Data Cloud Ecosystem with Snowflake to Advance AI-Driven Business Innovation, SAP Snowflake, Snowflake, zero-copy data
(IN BRIEF) AstraZeneca’s Alexion has secured European Commission approval for Koselugo (selumetinib), the first targeted therapy available to adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The approval is based on the KOMET Phase III trial, … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 treatment, Alexion, American Society of Clinical Oncology, APHP, ASCO 2025, AstraZeneca, AstraZeneca Expands Rare Disease Portfolio with EU Approval of Koselugo for Adults with NF1 Tumours, European Commission approval, European Union, Henri Mondor Hospital, Japan approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, Paris East University, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease therapy, selumetinib, The Lancet, tumour response rate, UPEC
Europe’s RNA immunotherapy sector is gaining speed with new in vivo CAR-T and mRNA vaccine trials. Germany approved the region’s first in vivo CAR-T study, marking regulatory progress. The UK’s Cancer Vaccine Launch Pad advances personalised mRNA cancer vaccine trials … Read the full press release
Posted in Belgium, Business, Germany, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, ATMP, autoimmunity, BioNTech, BioNTech’s BNT116, biotechnology, Cancer Vaccine Launch Pad, CAR-T therapy, clinical trials, CREATE Medicines, CureVac, EMA, EU-FAB, Europe, Europe Becomes a Hub for Next-Generation RNA Immunotherapy with Strong Clinical and Industrial Momentum, Europe’s Biotech Sector Accelerates RNA-Based Immunotherapy with Breakthroughs in CAR-T and mRNA Vaccines, Europe’s RNA Immunotherapy Industry Poised for Expansion as BioNTech AstraZeneca and CREATE Medicines Lead Advances, Europe’s RNA Immunotherapy Landscape Expands with First In Vivo CAR-T Trial and Growing mRNA Vaccine Efforts, Europe’s RNA Immunotherapy Pipeline Gains Scale as Regulators and Industry Push for Next-Gen Cancer Treatments, fibrosis, Germany, Imfinzi, immuno-oncology, in vivo CAR-T, INT2104, mRNA Vaccines, multi-lineage immune programming, Myeloid Therapeutics, NHS England, oncology, pharma, RNA immunotherapy, RNA Immunotherapy in Europe: Emerging Trials Strategic Mergers and a Clearer Regulatory Path, RNA Immunotherapy Takes Hold in Europe as BioNTech-CureVac Deal and CREATE Medicines Expansion Signal Maturity, RNA therapeutics, RNA-based therapies, United Kingdom
(IN BRIEF) AstraZeneca reported positive Phase III Bax24 trial results showing that baxdrostat achieved a significant and clinically meaningful reduction in 24-hour ambulatory systolic blood pressure in patients with treatment-resistant hypertension. The once-daily oral therapy was well tolerated and maintained … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Advancing Toward Regulatory Submission, AHA 2025, aldosterone, aldosterone synthase inhibitor, ambulatory blood pressure, American Heart Association, AstraZeneca, AstraZeneca’s Baxdrostat Achieves Significant Blood Pressure Reduction in Phase III Bax24 Trial, AstraZeneca’s Baxdrostat Achieves Strong Blood Pressure Reduction in Phase III Bax24 Trial for Resistant Hypertension, Bax24, Baxdrostat, Baxdrostat Delivers Significant 24-Hour Blood Pressure Control in Phase III Study, BaxHTN, Bryan Williams, cardiovascular health, Chronic kidney disease, clinical trial, heart failure prevention, Hypertension Treatment, Phase III results, primary aldosteronism, resistant hypertension, rHTN, SBP, Sharon Barr, systolic blood pressure
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review by the FDA for the first-line treatment of HER2-positive metastatic breast cancer. The application is supported by data from the … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, breakthrough therapy designation, cancer treatment innovation, Daiichi Sankyo, DESTINY-Breast09, Enhertu, Enhertu plus pertuzumab moves closer to first-line approval in HER2-positive metastatic breast cancer after FDA Priority Review acceptance, FDA, FDA grants Priority Review to Enhertu plus pertuzumab for 1st-line HER2-positive metastatic breast cancer following DESTINY-Breast09 success, HER2-positive breast cancer, Ken Takeshita, metastatic breast cancer, oncology, pertuzumab, Priority Review, progression-free survival, Real-Time Oncology Review, Susan Galbraith, THP regimen, trastuzumab deruxtecan
(IN BRIEF) Alfa Laval is hosting ESS Innovation Day 2025 on 19 August in Lund, Sweden, an event that unites research directors from leading companies and universities to explore how neutron science from the European Spallation Source (ESS) can help … Read the full press release
Posted in Business, Energy, Gas & Oil, Financial, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Media, News, Sweden, Technology
Tagged academia and industry, Alfa Laval, Asker Healthcare, AstraZeneca, Chalmers University, Emma Adlerton, ESS, ESS Innovation Day 2025, European competitiveness, European Spallation Source, Helmut Schober, Hitachi Energy, industrial innovation, Jarla Invest, Julien Gennetier, Laurence Mott, Lund, Mene Pangalos, neutron science, R&D collaboration, sustainability, Sweden, Tetra Pak, Uppsala University
(IN BRIEF) The FDA has accepted AstraZeneca’s sBLA for Imfinzi as a perioperative immunotherapy regimen in resectable early‑stage and locally advanced gastric and GEJ cancers, granting Priority Review with a decision expected in Q4 2025. The application leverages MATTERHORN Phase III data … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged 2025 decision, adjuvant, AstraZeneca, breakthrough therapy designation, clinical paradigm shift, durvalumab, early-stage, EFS hazard ratio, event-free survival, FDA priority review, FLOT chemotherapy, gastric cancer, gastroesophageal junction cancer, high unmet need, Imfinzi, Levi Garraway, locally advanced, MATTERHORN Phase III, neoadjuvant, overall survival, Perioperative Immunotherapy, resectable, sBLA, Susan Galbraith
(IN BRIEF) AstraZeneca’s Trixeo Aerosphere has received a positive opinion from the EMA’s CHMP for use with a new propellant that offers a 99.9% reduction in Global Warming Potential compared to traditional formulations. Trixeo becomes the first pressurised metered-dose inhaler … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Ambition Zero Carbon, AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, Breztri, BTK inhibitor, budesonide, Calquence, chemoimmunotherapy, CHMP, chronic lymphocytic leukaemia, climate action in pharma, clinical trial, CLL, COPD, Dave Fredrickson, EMA, environmental sustainability, European approval, European Commission approval, European Union, fixed-duration regimen, formoterol fumarate, Frederik Trinkmann, glycopyrronium, hematologic diseases, hematology, Honeywell, inhalers, leukemia, low GWP, next-generation propellant, obinutuzumab, oncology, pMDI, progression-free survival, Respiratory Care, Ruud Dobber, Susanna Palkonen, Sustainable Healthcare, treatment option, Trixeo Aerosphere, venetoclax
(IN BRIEF) Final overall survival results from AstraZeneca’s FLAURA2 Phase III trial confirm that combining Tagrisso with chemotherapy significantly improves survival for patients with first-line advanced EGFR-mutated NSCLC. The data reinforce Tagrisso as the foundational therapy in this setting, building … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADAURA trial, ADAURA2, adjuvant therapy, AstraZeneca, cancer survival, chemotherapy, EGFRm NSCLC, EMA, FDA, FLAURA2 trial, global clinical trial, LAURA trial, lung cancer treatment, NeoADAURA, non-small cell lung cancer, oncology, osimertinib, overall survival, Pasi A. Jänne, pemetrexed, platinum-based treatment, progression-free survival, Susan Galbraith, Tagrisso, targeted therapy
(IN BRIEF) The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) combined with gemcitabine and cisplatin as neoadjuvant therapy, followed by Imfinzi adjuvant monotherapy, for adults with resectable muscle-invasive bladder cancer. This approval is anchored in NIAGARA Phase III trial data … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged adjuvant monotherapy, AstraZeneca, cisplatin, curative intent, Dave Fredrickson, durvalumab, ESMO, European Commission, event-free survival, gemcitabine, Imfinzi, immunotherapy, MIBC, Michiel Van der Heijden, muscle-invasive bladder cancer, neoadjuvant chemotherapy, New England Journal of Medicine, NIAGARA Phase III, NMIBC, overall survival, radical cystectomy
(IN BRIEF) Sanofi has launched early global shipments of Beyfortus (nirsevimab) in anticipation of the 2025–2026 RSV season, enabling healthcare providers to begin immunizations well before the typical onset of infections in November. In collaboration with AstraZeneca, Sanofi has significantly … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AstraZeneca, Beyfortus, EU label, extended protection, global distribution, hospitalizations, infant immunization, lower respiratory tract disease, monoclonal antibody, newborn care, nirsevimab, pediatric health, public health, real-world studies, respiratory syncytial virus, RSV, RSV season, Sanofi, Thomas Triomphe, Vaccine Innovation, vaccine supply chain
(IN BRIEF) AstraZeneca’s Calquence, in combination with venetoclax, with or without obinutuzumab, has been approved by the European Commission for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The approval follows the positive results from the … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, BTK inhibitor, Calquence, chemoimmunotherapy, chronic lymphocytic leukaemia, clinical trial, CLL, Dave Fredrickson, European Commission approval, European Union, fixed-duration regimen, hematologic diseases, hematology, leukemia, obinutuzumab, oncology, progression-free survival, treatment option, venetoclax
(IN BRIEF) The POTOMAC Phase III trial results show that adding Imfinzi to standard BCG induction and maintenance therapy improves disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The combination demonstrated significant benefits over BCG alone, with … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Bacillus Calmette-Guérin, BCG, bladder cancer, cancer treatment, clinical trial, Cristian Massacesi, disease progression, disease-free survival, durvalumab, high-risk bladder cancer, Imfinzi, immunotherapy, Maria De Santis, NMIBC, non-muscle-invasive bladder cancer, Phase III Trial, POTOMAC
(IN BRIEF) Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly improves lung function in patients with uncontrolled asthma, compared to dual-combination ICS/LABA therapy. The trials demonstrate the potential of Breztri … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alberto Papi, asthma, AstraZeneca, BioPharmaceuticals R&D, Breztri Aerosphere, budesonide/glycopyrronium/formoterol, chronic respiratory disease, clinical trials, COPD, global asthma statistics, ICS/LABA, KALOS, LOGOS, lung function, Phase III, regulatory authorities, Sharon Barr, triple-combination therapy
(IN BRIEF) At ESCMID Global 2025 in Vienna, AstraZeneca will present a comprehensive data package from its Vaccines & Immune Therapies portfolio, featuring 13 abstracts across oral and poster presentations. The Company aims to demonstrate its progress in developing innovative … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, AZD6563, Benjamin Moutier, bronchiectasis, COVID-19, ESCMID Global 2025, Fluenz, FluMist, hMPV, immunizations, infectious diseases, Klebsiella pneumoniae, monoclonal antibodies, mRNA, MRSA, preclinical data, Pseudomonas aeruginosa, Real-World Data, respiratory viral infections, RSV, serious bacterial infections, Staphylococcus aureus, Vaccines & Immune Therapies, variant-agnostic threshold, Vienna
(IN BRIEF) The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherapy significantly improves event-free survival in patients with resectable gastric and gastroesophageal junction cancers compared to standard chemotherapy alone. Interim findings … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adjuvant, AstraZeneca, clinical trial, Cristian Massacesi, durvalumab, early-stage, EFS, event-free survival, FLOT chemotherapy, gastric cancer, gastroesophageal junction, GEJ cancers, global, Imfinzi, immunotherapy, locally advanced, MATTERHORN, Memorial Sloan Kettering, neoadjuvant, OS, overall survival, pathologic complete response, PCR, Phase III Trial, randomized, resectable, safety profile, tumor regression, Yelena Y. Janjigian
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?